0
0
0
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
6/14/2024, 8:05 AM
Summary of Bill HJRES 145
Bill 118 hjres 145 is a piece of legislation that aims to disapprove of a rule submitted by the Food and Drug Administration (FDA) regarding "Medical Devices; Laboratory Developed Tests." The rule in question falls under chapter 8 of title 5, United States Code, which governs the regulatory process for federal agencies.
The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.
If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.
If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
Read the Full Bill
Current Status of Bill HJRES 145
Bill HJRES 145 is currently in the status of Bill Introduced since May 16, 2024. Bill HJRES 145 was introduced during Congress 118 and was introduced to the House on May 16, 2024. Bill HJRES 145's most recent activity was Referred to the House Committee on Energy and Commerce. as of May 16, 2024
Bipartisan Support of Bill HJRES 145
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
8Democrat Cosponsors
0Republican Cosponsors
8Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HJRES 145
Primary Policy Focus
HealthAlternate Title(s) of Bill HJRES 145
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Comments
Sponsors and Cosponsors of HJRES 145
Latest Bills
National Defense Authorization Act for Fiscal Year 2026
Bill S 1071December 13, 2025
Enduring Justice for Victims of Trafficking Act
Bill S 2584December 13, 2025
Technical Corrections to the Northwestern New Mexico Rural Water Projects Act, Taos Pueblo Indian Water Rights Settlement Act, and Aamodt Litigation Settlement Act
Bill S 640December 13, 2025
Incentivizing New Ventures and Economic Strength Through Capital Formation Act of 2025
Bill HR 3383December 13, 2025
BOWOW Act of 2025
Bill HR 4638December 13, 2025
Northern Mariana Islands Small Business Access Act
Bill HR 3496December 13, 2025
Wildfire Risk Evaluation Act
Bill HR 3924December 13, 2025
Energy Choice Act
Bill HR 3699December 13, 2025
ESTUARIES Act
Bill HR 3962December 13, 2025
Improving Interagency Coordination for Pipeline Reviews Act
Bill HR 3668December 13, 2025
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Bill SJRES 82June 12, 2024




